TABLE 3.
Distribution of partial continuous and categorical data in the original dataset (n = 2,142).
| Continuous data | Values [median (min–max)] | Missing [n (%)] | Categorical data | Values | Distribution [n (%)] |
|---|---|---|---|---|---|
| C (OLZ) (ng/ml) | 26.43 (2.00–127.31) | 0 (0%) | Gender | Male | 1235 (57.66%) |
| Age (years) | 47 (12–94) | 0 (0%) | Female | 907 (42.34%) | |
| BW (kg) | 61 (26–121) | 462 (21.57%) | Smoking history | Yes | 308 (14.38%) |
| Daily dose of OLZ (mg) | 15 (1.25–30) | 0 (0%) | No | 1347 (62.89%) | |
| Time of TDM blood sampling after first administration of OLZ (days) | 18 (0–483) | 0 (0%) | Unknown | 487 (22.73%) | |
| ALT (U/L) | 18 (3–632) | 1021 (47.67%) | Diagnosis of schizophrenia | Yes | 999 (46.64%) |
| Na (mmol/L) | 140.3 (121.0–150.0) | 1046 (48.83%) | No | 1143 (53.36%) | |
| K (mmol/L) | 3.99 (2.20–5.21) | 1046 (48.83%) | Co-administration of valproic acid | Yes | 778 (36.32%) |
| Cr (μmol/L) | 70 (28–203) | 1067 (49.81%) | No | 1364 (63.68%) | |
| MONO# (×109/L) | 0.49 (0.07–2.07) | 985 (45.99%) | |||
| C (Valproic acid) (mg/L) | 0.00 (0.00–150.00) | 231 (10.78%) |